Trials / Completed
CompletedNCT00637039
Study of AZD8931 in Patients With Advanced Solid Malignancies
A Phase 1, Open-label, Multiple-dose, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD8931 in Patients With Advanced Solid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to explore the safety and tolerability of multiple ascending doses (MAD) of AZD8931 in patients with advanced solid malignancies
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD8931 | Tolerability and Pharmacokinetics of AZD8931 in Patients with Advanced Solid Malignancies. |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2009-06-01
- Completion
- 2012-12-01
- First posted
- 2008-03-17
- Last updated
- 2013-03-12
Locations
3 sites across 2 countries: Germany, Russia
Source: ClinicalTrials.gov record NCT00637039. Inclusion in this directory is not an endorsement.